𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice

✍ Scribed by K. ØVLISEN; A. T. KRISTENSEN; L. A. VALENTINO; N. HAKOBYAN; J. INGERSLEV; M. TRANHOLM


Book ID
109152512
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
240 KB
Volume
6
Category
Article
ISSN
1538-7933

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Influence of aggregation on immunogenici
✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg

Effect of route of administration of hum
✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,